Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




RNA Libraries Available to Researchers

By Biotechdaily staff writers
Posted on 30 Mar 2004
Vast libraries of short segments of ribonucleic acid (RNA) that can be used to turn off individual human and mouse genes to study their function are now being made available to laboratories studying human biology and disease. More...
Two independent research groups reported their respective RNA interference (RNAi) libraries in the March 25, 2004, issue of Nature.

To construct a library of mammalian genes for short hairpin RNA molecules, researchers first had to settle on an optimal design for a short-hairpin-RNA molecule. "We tested a lot of different things: for example, the length of the hairpin, the loop structure, the structure of the transcript, and what promoters to use,” said Gregory Hannon of the Cold Spring Laboratory (NY, USA; www.cshl.org) and one of the investigators. "And we arrived at an optimal structure for this phase of the science.”

Once an optimized basic design of the short hairpin RNA molecule was finished, the researchers produced a library of genes for short hairpin RNAs that could target 9,610 human genes and 5,563 mouse genes. The genes chosen were those likely to be involved in human disease or to be key molecular switches in the cell. This library of genes was then integrated into a retroviral vector capable of shuttling the genes into other cell types. The investigators also incorporated a DNA "bar-coding” system, by which each RNA molecule can be tagged with a unique DNA sequence. By determining the sequence of a given bar code, library researchers can identify which RNA molecule among the thousands in the library is switching off the activity of a particular gene.

The retroviral vectors, however, were not efficient for getting genetic short hairpin RNAs into all cell types. A new technique called "mating-assisted genetically integrated cloning” (MAGIC) greatly assisted the transfer of the library into all cell types via bacterial mating.

In order to validate that the library worked in human cells, the investigators tested it in a genetic screen designed to report defects in human proteasome function. The proteasome is a key component of the machinery by which the cell breaks down unwanted proteins. "This was a thorough test of the system because there are a great number of different genes whose loss could interfere with proteasome function,” said Dr. Stephen Elledge, of Harvard Medical School (Boston, MA, USA; www.med.harvard.edu), who worked with Dr. Hannon's group. "We found quite a few genes, and concluded that the library had worked quite efficiently as a screening tool.”

Current efforts are aimed at increasing the number of human genes targeted by the library, say the investigators. They emphasized that the current and future libraries will be made available to the research community at a nominal cost through Open Biosystems, Inc., in Huntsville (AL, USA; www.openbiosystems.com).

"For the first time, this give us the opportunity to do a version of forward genetics in mammalian cells, where we can look at hypomorphic mutations, ranging from mild to severe, and their consequences on phenotypes, on what will eventually evolve to a genome-wide scale,” noted Dr. Hannon. "Thus, these libraries will evolve into an important resource for the research community.” Drs. Hannon and Elledge led the first group developing a library, while Dr. Rene Bernards of The Netherlands Cancer Institute (Amsterdam; www.nki.nl) led a second group.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.